Home » Authors » Aaron Lorenzo

Aaron Lorenzo

Articles

ARTICLES

Aquavan's Efficacy Confirmed In Phase III Bronchoscopy Trial

March 21, 2007

By Aaron Lorenzo

Around and about the Beltway: House subcommittee advances genetic discrimination measure

March 20, 2007

By Aaron Lorenzo

Acadia Stock Doubles On Good Phase IIb Data In Schizophrenia

March 20, 2007

By Aaron Lorenzo

Acadia Pharmaceuticals Inc. saw its market cap double Monday following positive Phase IIb findings showing that its investigational compound ACP-103 improved the efficacy of a widely prescribed schizophrenia drug and also minimized its side effects. (BioWorld Today)

Acadia Stock Doubles On Good Phase IIb Data In Schizophrenia

March 20, 2007

By Aaron Lorenzo

Acadia Pharmaceuticals Inc. saw its market cap double Monday following positive Phase IIb findings showing that its investigational compound ACP-103 improved the efficacy of a widely prescribed schizophrenia drug and also minimized its side effects. (BioWorld Today)

House Subcommittee Advances Genetic Discrimination Measure

March 19, 2007

By Aaron Lorenzo

House Subcommittee Advances Genetic Discrimination Measure

March 19, 2007

By Aaron Lorenzo

Tykerb Not Yet Positioned To Compete With Herceptin

March 16, 2007

By Aaron Lorenzo

Tykerb Not Yet Positioned To Compete With Herceptin

March 16, 2007

By Aaron Lorenzo

Senate Panel Jointly Looks At Safety Bill And PDUFA

March 15, 2007

By Aaron Lorenzo

Senate Panel Jointly Looks At Safety Bill And PDUFA

March 15, 2007

By Aaron Lorenzo

View All Articles by Aaron Lorenzo

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 8, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for May 8, 2025.
100 days of uncertainty
BioWorld
The first 100 days of the Trump administration have been nothing short of chaotic, both in the U.S. and throughout the world. Shining a light through the...
AACR 2025: Induced proximity strategy, beyond degraders
BioWorld
Targeted protein degradation has yet to notch its first approval. But with more than two dozen agents now in clinical trials, the strategy’s ultimate clinical...
NME Digest: Q1 2025
BioWorld
A quarterly dynamic table featuring new molecular entities (NMEs) revealed for the first time in current literature, at congresses and in company communications...